'Give RSV drug to highest risk toddlers'
Under-twos at highest risk of respiratory syncytial virus (RSV) should be given the monoclonal antibody palivizumab, Government vaccine advisers have agreed.
The Joint Committee on Vaccination and Immunisation has recommended all under-twos with severe chronic lung disease on home oxygen during the RSV season are given the monoclonal antibody.
Prescribing the drug was likely to reduce hospital admissions in the group by 39 per cent and be cost neutral to the NHS, the committee said at its last meeting. It is also considering extending the drug's use in children who are not on home oxygen.